| Literature DB >> 17828712 |
Helen M Baldan1, Helene J De Rosa, Iguatemy L Brunetti, Valdecir F Ximenes, Rosângela G P Machado.
Abstract
Tuberculosis chemotherapy involves combination of the drugs isoniazid (INH), rifampicin (RMP) and pyrazinamide (PYR) for a 6-month period. The present work investigated the influence of RMP and PYR on the pharmacokinetic parameters of INH when groups of rats were pre-treated for 21 days with INH alone or in combination with RMP and/or PYR, in the following amounts per kg body weight: INH 100 mg; INH 100 mg+RMP 100 mg; INH 100 mg+PYR 350 mg; INH 100 mg+PYR 350 mg+RMP 100 mg. It was found that the co-administration of PYR caused an increase in the INH distribution volume (V(d)/F), half-life of elimination (t(1/2beta)) and clearance (Cl(T)/F), and a decrease in the area under curve 0 to 24 h (AUC). Co-administration of RMP caused an increase in the Cl(T)/F and a decrease in the AUC. The combination INH+PYR+RMP caused an increase in the Cl(T)/F and a decrease in the AUC. These significant pharmacokinetic interactions between the tuberculostatic drugs might be related to differences in the therapeutic and toxic effects. (c) 2007 John Wiley & Sons, Ltd.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17828712 DOI: 10.1002/bdd.570
Source DB: PubMed Journal: Biopharm Drug Dispos ISSN: 0142-2782 Impact factor: 1.627